



1st Quarter of Fiscal 2016 Financial Results Conference Call

August 1, 2016



◆ Overview of 1st Quarter FY2016 Financial Results

Koji Hanasaki, Ph.D.

Corporate Officer, Senior Vice President
Finance & Accounting Department

◆ Action Plan to Achieve FY2016 Targets

Takuko Sawada

Director of the Board, Senior Executive Officer,
Senior Vice President
Corporate Strategy Division

◆ Overview of 1st Quarter FY2016 Financial Results

Koji Hanasaki, Ph.D.

Corporate Officer, Senior Vice President
Finance & Accounting Department

◆ Action Plan to Achieve FY2016 Targets

Takuko Sawada



Director of the Board, Senior Executive Officer,
Senior Vice President
Corporate Strategy Division

Summary: Good Start to Achieve Sales Target



◆ Sales: **73.2 B yen** (50.5%)
vs. 1H forecasts

◆ Royalty* income: **20.8 B yen** (48.8%)
vs. 1H forecasts
(Significantly exceeded the royalty income level of FY2015 because of the strong HIV franchise sales by ViiV Healthcare)




Summary: Good Start to Achieve Profit Targets




- ◆ Operating income: **18.0 B yen** (54.7%) vs. 1H forecasts
- ◆ Ordinary income: **16.7 B yen** (50.6%) vs. 1H forecasts
- ◆ Profit attributable to owners of parent: **12.5 B yen** (59.7%) vs. 1H forecasts


Operating income (1Q)



Ordinary income (1Q)



Profit attributable to owners of parent (1Q)



Financial Results (Consolidated)



(Units: B yen)

	FY2016				FY2015	YoY	
	full year forecasts	1H forecasts	Apr-Jun results	Progress vs. 1H forecasts (%)	Apr-Jun results	change (%)	change
Sales	318.0	145.0	73.2	50.5	63.9	14.6	9.3
Operating income	91.5	33.0	18.0	54.7	12.5	43.9	5.5
Ordinary income	101.5	33.0	16.7	50.6	14.6	14.3	2.1
Profit attributable to owners of parent	71.0	21.0	12.5	59.7	9.7	29.8	2.8

Exchange rate (average)	FY2016 forecasts	FY2016 Apr-Jun results
USD (\$) – JPY (¥)	110	108.2
EUR (€) – JPY (¥)	130	122.1
GBP (£) – JPY (¥)	155	155.2

Sales of Main Merchandise and Finished Goods (Consolidated)



(Units: B yen)

	1H forecasts	FY2016 Apr-Jun results	Progress vs. 1H forecasts (%)	FY2015 Apr-Jun results	Y on Y change (%)
Prescription drugs	76.3	39.9	52.3	39.7	0.5
Crestor®	20.9	11.4	54.7	10.6	7.5
Cymbalta®	8.9	4.4	49.6	3.5	27.0
Irbetan franchise®	7.4	4.2	56.7	4.1	3.1
Total of 3 key products	37.2	20.0	53.9	18.2	10.2
OxyContin® franchise	5.5	2.6	46.8	2.6	(0.1)
Finibax®	2.0	0.9	46.0	1.0	(5.6)
Pirespa®	3.3	1.6	49.6	1.6	3.9
Rapiacta®	0.1	0.1	124.2	(0.0)	-
Total of 7 strategic products [percent of sales]	48.1 [63.0%]	25.3 [63.3%]	52.6	23.3 [58.7%]	8.5
Overseas subsidiaries/export	12.4	6.5	52.8	7.2	(8.1)
Shionogi Inc.	6.0	3.6	60.4	4.4	(17.4)
Osphena®	2.6	1.2	46.4	1.3	(5.4)
Contract manufacturing	5.3	2.6	48.7	1.5	71.9
OTC and quasi-drugs	3.5	1.7	48.6	1.2	37.0
Royalty income	46.3	21.8	47.0	13.5	60.8
Royalty income for the sales of Crestor® and HIV franchise	42.5	20.8	48.8	12.6	64.5
Crestor®	16.5	10.5	63.9	11.2	(6.2)
HIV franchise	26.0	10.2	39.3	1.4	637.5
Others	1.2	0.6	52.8	0.7	(15.7)
Total	145.0	73.2	50.5	63.9	14.6

◆ vs. 1Q FY2015

Prescription drugs

Increased due to growth of the seven strategic products
 – Crestor® OD Tablets were launched
 – Cymbalta® contributed in pain area

Shionogi Inc.

Decreased due to divestiture of existing products in FY2015

Contract manufacturing

Increased due to expansion of API for dolutegravir

OTC and quasi-drugs

Increased due to the launch of ISODINE® brands

Royalty income

Increased due to strong sales of HIV franchise worldwide

Statement of Income (Consolidated)



(Units: B yen)

◆ vs. 1Q FY2015

	1H forecasts	FY2016 Apr-Jun results	Progress vs. 1H forecasts (%)	FY2015 Apr-Jun results	Y on Y change (%)
Sales	145.0	73.2	50.5	63.9	14.6
[Royalty* income]	42.5	20.8	48.8	12.6	64.5
	26.6 [37.6]	27.1 [37.8]		28.3 [35.2]	
Cost of sales	38.5	19.8	51.5	18.0	9.8
SG&A expenses	73.5	35.3	48.0	33.3	6.1
	50.7	48.3		52.1	
Selling & general expenses	49.0	22.7	46.3	22.7	0.2
	16.9	17.3		16.6	
R&D expenses	24.5	12.6	51.5	10.6	18.7
	22.8	24.7		19.6	
Operating income [Excluding royalty* income]	33.0 (9.5)	18.0 (2.7)	54.7	12.5 (0.1)	43.9
Non-operating income and expenses	-	L1.4	-	P2.1	-
	22.8	22.8		22.9	
Ordinary income	33.0	16.7	50.6	14.6	14.3

Cost of sales (Cost of sales ratio)

Cost of sales ratio: Improved 1.2%

- Increase in royalty income

Cost of sales ratio excluding royalty income: Increased 2.6%

- Product mix
- NHI price revisions
- Expansion of contract manufacturing of API for dolutegravir

SG&A expenses

Strategic investment by focusing on efficiency and prioritization and total cost management

Selling & general expenses ratio: Down 4.5%

R&D expenses ratio: Up 0.7%

Non-operating income and expenses

Foreign exchange losses of foreign-currency asset

◆ Overview of 1st Quarter FY2016 Financial Results

Koji Hanasaki, Ph.D.

Corporate Officer, Senior Vice President
Finance & Accounting Department

◆ Action Plan to Achieve FY2016 Targets

Takuko Sawada

Director of the Board, Senior Executive Officer,
Senior Vice President
Corporate Strategy Division

Basic Strategy in FY2016 to Achieve SGS2020



Key actions to complete “Evolution of core business” in SGS2020

Continue achieve bottom-line targets
and

Achieve top-line targets in Japanese/overseas businesses

Positioning for FY2016

Accelerate strengthening of business base and create future growth drivers, in preparation for upcoming patent expirations of strategic products after FY2017

Basic Strategy in FY2016

Continue growth based on increasing royalty income and improved cost management
and

Strengthen and enhance Japanese/overseas business

◆ Focus resources on growth drivers

Cymbalta®

- Depression and depressive symptoms
 - Expansion of sales as one of the first treatment options
- Pain associated with fibromyalgia/pain associated with chronic low back pain
 - Establish a partnership between psychiatrists, orthopedic surgeons, etc.

Contribute to patients and medical treatment in pain/CNS areas
Support communication between pain and CNS physicians to promote proper use

◆ Strengthen business base

Crestor® OD Tablets

- Improve patient compliance using CMC technologies
- First NTE* program at Shionogi
- Maximize the value of Crestor®

Contribute to healthcare and maintain its growth as a top statin brand
by launching Crestor® OD Tablets

◆ Future growth driver

Naldemedine

- Preparing for the launch of naldemedine as a first in-house global product
- Start to explore partnering options to maximize the value of naldemedine

FDA: Acceptance of NDA in the US

(PDUFA date: March 23, 2017)

◆ Strengthen business base


Osphena®

- Only product with growing market share in a declining VVA market
- Focusing resources on high-potential areas
- Phase III clinical study for vaginal dryness

Continue to optimize promotional activities in the US, launched in Italy and preparing in Spain, and creating strategy for ASEAN countries

◆ Global sales trend

- Continuous strong global expansion exceeded forecast, reflecting its good efficacy, safety, adherence and resistance profile
- Ratio of US sales in total sales is about 2/3



◆ Impact of foreign exchange on royalty income

- **Foreign exchange reservations** to hedge the risk of exchange rate fluctuation at the beginning of FY2016
 - ⇒ **Reduced the negative impact of exchange rate** on royalty income
- Exchange rate fluctuations (£/¥ as well as \$/£) impact on royalty income
- Consider foreign exchange reservations to reduce the risk of exchange rate fluctuation after next fiscal year

Target Milestones for FY2016



Areas	Product	As of Apr. 1, 2016	Target for FY2016
Infectious disease	S-649266 Multidrug-resistant Gram-negative bacterial infections	Global: Phase II, III	US: NDA submission
	S-033188 Influenza virus infection	Japan: Phase II US: Phase I	Japan: Phase II completed US: Phase I completed Japan: Phase III initiated Global: Phase III initiated
Pain/CNS	Guanfacine hydrochloride ADHD (pediatric)	Japan: NDA submission	Japan: Approval
	Cymbalta® Pain associated with osteoarthritis	Japan: NDA submission	Japan: Approval
	Naldemedine Opioid-induced constipation	Japan/US: NDA submission	Japan/US: Approval
	Oxycodone Treatment of moderate to severe chronic pain	Japan: Phase III	Japan: NDA submission
	Oxycodone Tamper resistant formulation	Japan: Phase I completed	Japan: NDA submission
	Lisdexamfetamine ADHD (pediatric)	Japan: Phase III	Japan: Phase III completed
Metabolic disorder	S-237648 Obesity	Japan: Phase II	Japan: Phase II completed US: Phase I initiated
Frontier	Lusutrombopag Thrombocytopenia associated with chronic liver disease	Global: Phase III	Global: NDA submission
	S-222611 Malignant tumor	EU: Phase I/II	EU: Phase I/II completed

Appendix

- Financial Results -

Japan: Sales of Strategic Products



(Units: B yen)

	FY2016				Progress vs. 1H forecasts (%)	FY2015		Y on Y	
	full year forecasts	1H forecasts	Apr-Jun results	Apr-Jun results		Apr-Jun results	change (%)	change	
Crestor [®]	41.5	20.9	11.4	54.7	10.6	7.5	0.8		
Cymbalta [®]	19.3	8.9	4.4	49.6	3.5	27.0	0.9		
Irbetan [®] franchise	15.1	7.4	4.2	56.7	4.1	3.1	0.1		
Total of 3 key products	75.9	37.2	20.0	53.9	18.2	10.2	1.8		
OxyContin [®] franchise	10.5	5.5	2.6	46.8	2.6	(0.1)	(0.0)		
Finibax [®]	3.9	2.0	0.9	46.0	1.0	(5.6)	(0.1)		
Pirespa [®]	6.3	3.3	1.6	49.6	1.6	3.9	0.0		
Rapiacta [®]	2.3	0.1	0.1	124.2	(0.0)	-	0.1		
Total of 7 strategic products	99.0	48.1	25.3	52.6	23.3	8.5	2.0		
[percent of sales]	[62.5%]	[63.0%]	[63.3%]		[58.7%]				
Prescription drugs	158.2	76.3	39.9	52.3	39.7	0.5	0.2		

Sales of Main Merchandise and Finished Goods (Consolidated)



(Units: B yen)

	FY2016			Progress vs. 1H forecasts (%)	FY2015	Y on Y	
	full year forecasts	1H forecasts	Apr-Jun results		Apr-Jun results	change (%)	change
Prescription drugs	158.2	76.3	39.9	52.3	39.7	0.5	0.2
Overseas subsidiaries/export	24.7	12.4	6.5	52.8	7.2	(8.1)	(0.7)
Shionogi Inc.	12.4	6.0	3.6	60.4	4.4	(17.4)	(0.8)
Osphena®	5.3	2.6	1.2	46.4	1.3	(5.4)	(0.1)
Contract manufacturing	10.9	5.3	2.6	48.7	1.5	71.9	1.1
OTC and quasi-drugs	7.0	3.5	1.7	48.6	1.2	37.0	0.5
Royalty income	114.9	46.3	21.8	47.0	13.5	60.8	8.3
Royalty income for the sales of Crestor® and HIV franchise	95.0	42.5	20.8	48.8	12.6	64.5	8.2
Crestor®	33.0	16.5	10.5	63.9	11.2	(6.2)	(0.7)
HIV franchise	62.0	26.0	10.2	39.3	1.4	637.5	8.8
Others	2.4	1.2	0.6	52.8	0.7	(15.7)	(0.1)
Total	318.0	145.0	73.2	50.5	63.9	14.6	9.3

Statement of Income (Consolidated)



(Units: B yen)

	FY2016			Progress vs. 1H forecasts (%)	FY2015	Y on Y	
	full year forecasts	1H forecasts	Apr-Jun results		Apr-Jun results	change (%)	change
Sales	318.0	145.0	73.2	50.5	63.9	14.6	9.3
[Royalty* income]	95.0	42.5	20.8	48.8	12.6	64.5	8.2
	24.5 [35.0]	26.6 [37.6]	27.1 [37.8]		28.3 [35.2]		
Cost of sales	78.0	38.5	19.8	51.5	18.0	9.8	1.8
Gross profit	240.0	106.5	53.3	50.1	45.8	16.4	7.5
	46.7	50.7	48.3		52.1		
SG&A expenses	148.5	73.5	35.3	48.0	33.3	6.1	2.0
Selling & general expenses	98.5	49.0	22.7	46.3	22.7	0.2	0.0
R&D expenses	50.0	24.5	12.6	51.5	10.6	18.7	2.0
Operating income	91.5	33.0	18.0	54.7	12.5	43.9	5.5
[Excluding royalty* income]	(3.5)	(9.5)	(2.7)	-	(0.1)	-	(2.6)
Non-operating income and expenses	P10.0	-	L1.4	-	P2.1	-	(3.5)
	31.9	22.8	22.8		22.9		
Ordinary income	101.5	33.0	16.7	50.6	14.6	14.3	2.1

Note: Small numbers in red are percent of sales, and numbers in red provided in parentheses are percent of sales excluding royalties

* Royalty income from AstraZeneca and ViiV for the sales of Crestor® and HIV franchise

Appendix

- Pipeline -

Change in Pipeline (since May 2016)



Code No.	Indication	Phase	Area	Changes
Change of phase				
S-237648	Obesity	Phase II Phase I	Japan US	Japan: Phase II → Japan: Phase II, US: Phase I
Compound added to the list				
S-600918	Neuropathic pain	Phase I	Japan	

New Products to Lead Future Growth



Target milestone for launch of new product

FY2016	FY2017	FY2018
Japanese business		
<p>Crestor[®] OD tablet Cymbalta[®] Pain associated with chronic low back pain Pain associated with osteoarthritis ISODINE[®] brand ethical products</p>	<p>Naldemedine Guanfacine hydrochloride Oxycodone Tamper resistant formulation Moderate to severe chronic pain</p>	<p>S-033188 Lisdexamfetamine Actair[®] Pediatric patients with perennial allergic rhinitis</p>
US business		
	<p>Naldemedine S-649266 Lusutrombopag</p>	<p>Osphena[®] Vaginal dryness associated with postmenopausal VVA</p>
Global out-licensed products		
		<p>Dolutegravir + rilpivirine</p>

Pipeline (as of Aug. 2016)



Phase I		Phase II		Phase III		NDA submission
【Global】						
S-033188 Influenza virus Infection	S-120083 Inflammatory pain	S-649266 Multidrug-resistant Gram-negative bacterial infections	S-707106 Type2 diabetes	S-488210 Head and neck squamous cell carcinoma	S-649266 Multidrug-resistant Gram-negative bacterial infections	
S-237648 Obesity	S-117957 Insomnia	S-222611 Malignant tumor	S-588410 Bladder cancer	Osphena® Vaginal dryness associated with postmenopausal VVA	Lusutrombopag Thrombocytopenia	Naldemedine Opioid-induced constipation
【In Japan】						
Non-clinical	Oxycodone Tamper resistant formulation			S-649266 Multidrug-resistant Gram-negative bacterial infections		
	S-120083 Inflammatory pain	S-649266 Multidrug-resistant Gram-negative bacterial infections		Lisdexamfetamine ADHD (pediatric)	Guanfacine hydrochloride ADHD (adult)	Naldemedine Opioid-induced constipation
Antibody drug candidate against Pseudomonas	S-010887 Neuropathic pain	S-033188 Influenza virus Infection	S-237648 Obesity	Actair® Pediatric patients with perennial allergic rhinitis	Oxycodone Moderate to severe chronic pain	Cymbalta® Pain associated with osteoarthritis
NTE Inhalation	S-600918 Neuropathic pain	S-525606 Allergic rhinitis caused by Japanese cedar allergen	S-588410 Bladder cancer	S-555739 Allergic rhinitis	S-588410 Esophageal cancer	Guanfacine hydrochloride ADHD (pediatric)

Pipeline (as of Aug. 2016)



Non-clinical	Phase I	Phase II	Phase III	NDA submission
<p>【Out-licensed】</p> <div data-bbox="19 485 357 614" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>GSK3342830 Multidrug-resistant Gram-negative bacterial infections</p> </div> <div data-bbox="19 671 357 799" style="border: 1px solid black; padding: 5px;"> <p>Janssen/Shionogi Project compound Alzheimer's disease</p> </div>		<div data-bbox="782 335 1130 464" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>Cabotegravir + rilpivirine LAP Treatment for HIV infection</p> </div> <div data-bbox="782 492 1130 621" style="border: 1px solid black; padding: 5px;"> <p>Cabotegravir LAP Prevention for HIV infection</p> </div>	<div data-bbox="1168 485 1516 614" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p>Dolutegravir + rilpivirine Treatment for HIV infection</p> </div> <div data-bbox="1168 671 1516 799" style="border: 1px solid black; padding: 5px;"> <p>Janssen/Shionogi BACE inhibitor Alzheimer's disease</p> </div>	

Pipeline Information



Code No.	Generic name	Product name	Indication
S/GSK1349572	Dolutegravir	Tivicay®	HIV infection
—	Dolutegravir/abacavir/lamivudine	Triumeq®	HIV infection
S/GSK1265744 LAP	Cabotegravir	—	HIV infection
S-649266	—	—	Multidrug-resistant Gram-negative bacterial infections
S-033188	—	—	Influenza virus infection
S-8117	Oxycodone hydrochloride hydrate	OxyContin®	Moderate to severe chronic pain
S-297995	Naldemedine tosilate	—	Opioid-induced constipation
LY248686	Duloxetine hydrochloride	Cymbalta®	Depression and depressive symptoms, Pain associated with chronic low back pain, etc.
S-877503	Guanfacine hydrochloride	Intuniv® (US brand name)	ADHD
S-877489	Lisdexamfetamine	Vyvanse® (US brand name)	ADHD
S-888711	Lusutrombopag	Mulpleta®	Thrombocytopenia associated with chronic liver disease
S-524101	—	Actair®	Pediatric patients with perennial allergic rhinitis caused by HDM

Forward-Looking Statements



- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.